Ann Lab Med.  2012 Sep;32(5):331-338. 10.3343/alm.2012.32.5.331.

Clinical Usefulness of Cell-based Indirect Immunofluorescence Assay for the Detection of Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder

Affiliations
  • 1Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • 2Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. bjkim@skku.edu

Abstract

BACKGROUND
The presence of antibodies to aquaporin-4 (AQP4) has been identified as a key characteristic of neuromyelitis optica spectrum disorder (NMOSD), an autoimmune inflammatory demyelinating central nervous system (CNS) disorder. We evaluated the performance of a cell-based indirect immunofluorescence assay (CIIFA) for detecting AQP4 antibodies using antigen prepared with a recombinant AQP4 peptide transfection technique and assessed the usefulness of CIIFA for diagnosis of NMOSD in routine clinical practice.
METHODS
Forty-six serum samples from 36 patients as a comparison set and another 101 patients enrolled consecutively from a neurology clinic were included. CIIFA and fluorescence immunoprecipitation assays (FIPA) were performed. CIIFA was performed at 2 different institutions for comparison purposes.
RESULTS
CIIFA and FIPA sensitivity in the comparison set was 86% and 79% in neuromyelitis optica (NMO) patients and 55% and 36% in high-risk NMO patients, respectively. The semiquantitative titer measured by CIIFA correlated well with the arbitrary unit (fluorescence units [FU]) derived from FIPA (r=0.66). Titers measured by CIIFA and FIPA were elevated in NMO patients compared to high-risk NMO patients (1:240 vs. 1:180 and 8,390 vs. 4,059 FU, respectively). The frequency of AQP4 antibody detection by CIIFA in 101 consecutively enrolled patients was 100% in NMO and 23% in high-risk NMO patients, while only 4.6% in control patients, including those with multiple sclerosis.
CONCLUSIONS
Detection of AQP4 antibodies by CIIFA provides sensitive and highly specific diagnostic information for NMO and high-risk NMO patients, which can be used to differentiate these conditions from other demyelinating CNS diseases.

Keyword

Neuromyelitis optica; Aquaporin 4; Indirect immunofluorescence assay; Immunoprecipitation assay

MeSH Terms

Adult
Aged
Antibodies/*blood
Aquaporin 4/*immunology
Female
*Fluorescent Antibody Technique, Indirect
Humans
Male
Middle Aged
Neuromyelitis Optica/*diagnosis
Reagent Kits, Diagnostic

Figure

  • Fig. 1 Cell-based indirect immunofluorescence assay (CIIFA) for aquaporin-4 (AQP4) antibody detection with AQP4-transfected HEK 293 cell line as a substrate. Representative samples showing an intensity of w+ to 4+ are provided above. W+ was assigned when the intensity of fluorescence was less than 1+. Of note, fluorescence was also observed in round cells, which might not reflect healthy, viable HEK cells during slide preparation.

  • Fig. 2 Distribution of AQP4 antibody values in 46 comparison samples. (A) Correlation of the results between the semiquantitative titer of the cell-based indirect immunofluorescence assay (CIIFA) and the quantitative value derived from the fluorescence immunoprecipitation assay (FIPA) based on arbitrary fluorescence units (FU). (B) Titers of AQP4 antibody measured by CIIFA in sera of patients with various diseases. Abbreviations: MS, multiple sclerosis; NMO, neuromyelitis optica; OND, other neurological diseases.

  • Fig. 3 The fluorescence intensity of AQP4 antibodies measured by the cell-based indirect immunofluorescence assay (CIIFA) in sera of 101 patients with various diseases. There were only 3 AQP4 antibody-positive patients (*) among non-NMO and non-high-risk NMO patients. Weak positive intensity was not considered to be a significant positive result. Abbreviations: ADEM, acute disseminating encephalomyelitis; AND, autoimmune neurologic diseases; CIS, clinical isolated syndrome; LETM, longitudinal extensive transverse myelitis; MS, multiple sclerosis; NMO, neuromyelitis optica; OND, other neurological diseases; RON, recurrent optic neuritis.


Cited by  2 articles

Association of Optic Neuritis with Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis in Korea
HyoJeong Kim, Kyung-Ah Park, Sei Yeul Oh, Ju-Hong Min, Byoung Joon Kim
Korean J Ophthalmol. 2019;33(1):82-90.    doi: 10.3341/kjo.2018.0050.

Clinical Usefulness of a Cell-based Assay for Detecting Myelin Oligodendrocyte Glycoprotein Antibodies in Central Nervous System Inflammatory Disorders
Jin Myoung Seok, Patrick Waters, Mi Young Jeon, Hye Lim Lee, Seol-Hee Baek, Jin-Sung Park, Sa-Yoon Kang, Ohyun Kwon, Jeeyoung Oh, Byung-Jo Kim, Kyung-Ah Park, Sei Yeul Oh, Byoung Joon Kim, Ju-Hong Min
Ann Lab Med. 2024;44(1):56-63.    doi: 10.3343/alm.2024.44.1.56.


Reference

1. Devic E. Subacute myelitis complicated by optic neuritis. Bull Med. 1894. 8:1033–1034.
2. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999. 53:1107–1114.
Article
3. de Seze J, Stojkovic T, Ferriby D, Gauvrit JY, Montagne C, Mounier-Vehier F, et al. Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci. 2002. 197:57–61.
Article
4. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007. 6:805–815.
Article
5. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol. 2003. 2:117–127.
Article
6. Matsushita T, Isobe N, Matsuoka T, Shi N, Kawano Y, Wu XM, et al. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. Mult Scler. 2009. 15:834–847.
Article
7. Lennon V, Wingerchuk D, Kryzer T, Pittock S, Lucchinetti C, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004. 364:2106–2112.
Article
8. Lennon VA. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005. 202:473–477.
Article
9. Hiroaki Y, Tani K, Kamegawa A, Gyobu N, Nishikawa K, Suzuki H, et al. Implications of the aquaporin-4 structure on array formation and cell adhesion. J Mol Biol. 2006. 355:628–639.
Article
10. Paul F, Jarius S, Aktas O, Bluthner M, Bauer O, Appelhans H, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. 2007. 4:e133.
Article
11. Papeix C, Vidal JS, de Seze J, Pierrot-Deseilligny C, Tourbah A, Stankoff B, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler. 2007. 13:256–259.
Article
12. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005. 64:1270–1272.
Article
13. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002. 58:143–146.
Article
14. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010. 6:383–392.
Article
15. Waters P, Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J. 2008. 15:99–105.
16. Jarius S, Probst C, Borowski K, Franciotta D, Wildemann B, Stoecker W, et al. Standardized methods for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci. 2010. 291:52–56.
17. Hayakawa S, Mori M, Okuta A, Kamegawa A, Fujiyoshi Y, Yoshiyama Y, et al. Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol. 2008. 196:181–187.
Article
18. Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007. 130:1235–1243.
Article
19. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006. 66:1485–1489.
Article
20. Waters P, Jarius S, Littleton E, Leite MI, Jacob S, Gray B, et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol. 2008. 65:913–919.
Article
21. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002. 125:1450–1461.
22. Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med. 2006. 210:307–313.
Article
23. Fazio R, Malosio M, Lampasona V, De Feo D, Privitera D, Marnetto F, et al. Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. Mult Scler. 2009. 15:1153–1163.
Article
24. De Vidi I, Boursier G, Delouche N, Portalès P, Cadars E, Bouthier M, et al. Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. Clin Immunol. 2011. 138:239–246.
Article
25. Hinson SR, McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Pittock SJ. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol. 2009. 66:1164–1167.
Article
26. McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Hinson SR, Kryzer TJ, et al. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol. 2009. 66:1134–1138.
27. Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008. 65:78–83.
Article
28. Jarius S, Jacobi C, de Seze J, Zephir H, Paul F, Franciotta D, et al. Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler. 2011. 17:1067–1073.
Article
29. Hinson SR, McKeon A, Lennon VA. Neurological autoimmunity targeting aquaporin-4. Neuroscience. 2010. 168:1009–1018.
Article
30. Min JH, Kim HJ, Kim BJ, Lee KW, Sunwoo IN, Kim SM, et al. Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica. Mult Scler. 2009. 15:1069–1076.
Article
31. Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008. 131:3072–3080.
Article
Full Text Links
  • ALM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr